Review Article
Regulation of Src Family Kinases in Human Cancers
Table 1
Src inhibitors with other agents in clinical trials.
| Drug | Phase | Tumor type | Combination agent |
| Dasatinib | II | Advanced-NSCLC/Colorectal/Pancreatic/HNSCC/Breast/SCLC/Melanoma | — | II | Resectable NSCLC/HNSCC | Erlotinib | I-II | Advanced NSCLC | Erlotinib | I | Breast | Capecitabine | I | Breast | Paclitaxel | I-II | Prostate/castration resistant prostate cancer | Docetaxel | I | Colon | FOLFOX6/Cetuximab |
| Saracatinib | II | Prostate/Pancreatic/Osteosarcoma/Soft tissue sarcoma/Melanoma/Gastration-resistant prostate cancer/Thymoma/Colorectal/HNSCC | — | II | Advanced NSCLC/SCLC | Carboplatin/Paclitaxel | I | Advanced solid tumor | Cediranib | I-II | Pancreatic | Gemcitabine | II | Ovarian | Carboplatin | II | Prostate/Breast with bone metastasis | Zoledronic acid |
| Bosutinib | II | Breast | — | II | Breast | Exemestane | II | Breast | Letrozole/Capecitabine | I-II | Advanced solid tumor | Capecitabine |
| XL228 | I | Advanced solid tumor | — |
| KX2-391 | I | Advanced solid tumor/Lymphoma | — |
| AZM475271 | I-II | Pancreatic | — |
| XL999 | I | Advanced solid tumor | — |
|
|